Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Charles Briac Levaché"'
Autor:
Patricia K. Corey-Lisle, Marie-Pierre Desrosiers, Helen Collins, Margarita De La Orden, Krista A. Payne, Charles Briac Levaché, Patrick Dumont
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 6 (2014)
Objectives: To estimate the patient burden in terms of the time spent on outpatient red blood cell (RBC) transfusions indicated for chemotherapy induced-anaemia (CIA) in patients with cancer in France. Methods: A retrospective chart review of patient
Externí odkaz:
https://doaj.org/article/fc98d56c6bc44f01ab877244897385ff
Autor:
Adrien Grancher, Ludivine Beaussire, Sylvain Manfredi, Karine Le Malicot, Marie Dutherage, Vincent Verdier, Claire Mulot, Olivier Bouché, Jean-Marc Phelip, Charles-Briac Levaché, Philippe Deguiral, Sophie Coutant, David Sefrioui, Jean-François Emile, Pierre Laurent-Puig, Frédéric Bibeau, Pierre Michel, Nasrin Sarafan-Vasseur, Côme Lepage, Frederic Di Fiore
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, 2022, 12, pp.973167. ⟨10.3389/fonc.2022.973167⟩
Frontiers in Oncology, 2022, 12, pp.973167. ⟨10.3389/fonc.2022.973167⟩
International audience; Circulating tumor DNA (ctDNA) is reported to be promising in localized colorectal cancer (CRC). The present study aimed to retrospectively evaluate the impact of ctDNA in patients with a resected stage II CRC from the PROGIGE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6b6743fbeb13694023e9c31719d5e75
https://hal.sorbonne-universite.fr/hal-03906981/document
https://hal.sorbonne-universite.fr/hal-03906981/document
Autor:
Dominique Berton, Anne Floquet, Willy Lescaut, Gabriel Baron, Marie-Christine Kaminsky, Philippe Toussaint, Rémy Largillier, Aude-Marie Savoye, Jérôme Alexandre, Catherine Delbaldo, Emmanuelle Malaurie, Hugues Barletta, Claire Bosacki, Claire Garnier-Tixidre, Philippe Follana, Hortense Laharie-Mineur, Charles Briac Levache, Bruno Valenza, Agnès Dechartres, Delphine Mollon-Grange, Frédéric Selle
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study as
Externí odkaz:
https://doaj.org/article/759e5d59f76b40d9ba13a0b2c9ebd372